Trial Now Recruiting: Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer (NCT05168566)
WHY IT MATTERS
This trial offers access to a targeted therapy specifically designed for patients with non-small cell lung cancer carrying rare EGFR mutations (L861Q, G719X, S768I) who may have limited treatment options.
Researchers are testing a new drug called Sutetinib Maleate Capsule to treat advanced lung cancer in patients who have specific uncommon mutations in their cancer cells. This is a Phase 2 study, which means the drug has already been tested for safety in a small group and now researchers want to see how well it works in a larger group of about 99 patients. The study is currently accepting new participants at multiple hospitals.
NCT ID: NCT05168566 Status: RECRUITING Conditions: Non-small Cell Lung Cancer Phase: PHASE2 Enrollment: 99 Sponsor: Teligene US Summary: This is a Phase 2b, multicenter, open-label study to evaluate the safety and efficacy of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, Including L861Q, G719X, and/or S768I)
YOU CAN ACT ON THIS
If you have locally advanced or metastatic non-small cell lung cancer with one of the specified EGFR mutations (L861Q, G719X, or S768I), contact the study team at clinicaltrials.gov using NCT05168566 to learn about enrollment at sites near you.